Esperion Q3 2022 product rev $14.0M (+28% Y/Y); net loss $55.1M; CLEAR Outcomes trial finished

Esperion Therapeutics, Inc.

2022-Q3 EPS reported -$2.78 revenue$56,657,000

U.S. net product revenue $14.0M (up 28% YoY); total revenue $19.0M (up 32% YoY).
Net loss $55.1M ($0.81 diluted EPS) vs $69.4M loss ($2.62 EPS) in Q3 2021.
CLEAR Outcomes trial achieved last patient last visit in Oct 2022; topline results expected Jan 2023.
SG&A down 36% YoY to $25.0M; R&D up 15% to $29.1M; cash $239.3M (down $70M from Dec 2021).
Reaffirmed FY2022 OpEx guidance: total $220-240M including $25M stock-based comp.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Esperion Therapeutics, Inc. reported the third quarter ended September 30, 2022 results: revenue $19.0 million, net income net losses of $55.1 million, EPS $0.81. Guidance reaffirmed.

Period: the third quarter ended September 30, 2022
Revenue: $19.0 million
Net income: net losses of $55.1 million
EPS: $0.81
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Total revenue for the third quarter ended September 30, 2022, was $19.0 million

View on SEC.gov

Browse all earnings releases →

Esperion Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-22-027472

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.